CEMIP (E4JIZ) Rabbit Monoclonal Antibody #72197

CEMIP (KIAA1199, HYBID) was originally described in patients affected by nonsyndromic hearing loss due to point mutations (1). One important role of the protein is the catabolic metabolism of hyaluronan by binding and depolymerizing the high molecular weight hyaluronan to low molecular weight hyaluronan, which contributes to cancer progression and inflammatory disease development (2,3). CEMIP further facilitates cancer progression by promoting WNT/β-catenin, EGFR, and calcium signaling pathways through direct interaction with pathway components (4-7). Aberrant high expression of CEMIP is associated with various types of cancer, where it plays key roles in tumor initiation, progression, metastasis, and epithelial-mesenchymal transition (EMT) (8). High levels of secreted CEMIP are found in inflammatory arthritis, osteoarthritis, atherosclerosis, and inflammatory bowel disease (9,10). Gene knockdown of CEMIP reduces progression of these diseases. CEMIP is a potential target for cancer and inflammatory arthritis management (11,12).